Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06574984

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.

Official title: Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study

Key Details

Gender

MALE

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

900

Start Date

2024-11-10

Completion Date

2026-04-30

Last Updated

2026-02-13

Healthy Volunteers

No

Interventions

DRUG

Turoctocog alfa

Turoctocog alfa was administered intravenously.

Locations (7)

National centre for Hamophilia

Baghdad, Iraq

Novo Nordisk Investigational Site

Baghdad, Iraq

Basrah Haemoplhilia centre

Basra, Iraq

Hilla Haemophilia centre

Hillah, Iraq

Karbala Haemophilia centre

Karbala, Iraq

Kirkuk Centre for Cancer and Blood Disorders

Kirkuk, Iraq

Najaf Haemophilia Centre

Najaf, Iraq